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With an increasing number of institutions offering proton therapy, the number of 
multi-institutional clinical trials involving proton therapy will also increase in the coming 
years. The Radiological Physics Center monitors sites involved in clinical trials through 
the use of site visits and remote auditing with thermoluminescent dosimeters (TLD) and 
mailable anthropomorphic phantoms. Currently, there are no heterogeneous phantoms 
that have been commissioned to evaluate proton therapy. It was hypothesized that an 
anthropomorphic pelvis phantom can be designed to audit treatment procedures (patient 
simulation, treatment planning and treatment delivery) at proton facilities to confirm 
agreement between the measured dose and calculated dose within 5%/3mm with a 
reproducibility of 3%. A pelvis phantom originally designed for use with photon 
treatments was retrofitted for use in proton therapy. The relative stopping power (SP) of 
each phantom material was measured. Hounsfield Units (HU) for each phantom material 
were measured with a CT scanner and compared to the relative stopping power 
calibration curve. The tissue equivalency for each material was calculated. Two proton 
treatment plans were created; one which did not correct for material SP differences (Plan 
1) and one plan which did correct for SP differences (Plan 2). Film and TLD were loaded 
 vi  
into the phantom and the phantom was irradiated 3 times per plan. The measured values 
were compared to the HU-SP calibration curve and it was found that the stopping powers 
for the materials could be underestimated by 5-10%. Plan 1 passed the criteria for the 
TLD and film margins with reproducibility under 3% between the 3 trials. Plan 2 failed 
because the right-left film dose profile average displacement was -9.0 mm on the left side 
and 6.0 mm on the right side. Plan 2 was intended to improve the agreements and instead 
introduced large displacements along the path of the beam. Plan 2 more closely 
represented the actual phantom composition with corrected stopping powers and should 
have shown an agreement between the measured and calculated dose within 5%/3mm. 
The hypothesis was rejected and the pelvis phantom was found to be not suitable to 
evaluate proton therapy treatment procedures. 
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Chapter 1 
Introduction and Background 
1.1 Statement of Problem 
Proton therapy is quickly expanding in the United States, with new centers 
offering this course of treatment opening nearly every year. The motivation for proton 
therapy is its ability to deliver superior dose distributions when compared to the photon 
treatment alternative. It has been suggested that this will allow for a more conformal 
treatment plan in certain disease sites and the opportunity to escalate the dose to the 
tumor site without increasing dose to the surrounding normal tissues (Smith 2006). For 
this reason, along with the availability of medical insurance reimbursement and more 
affordable proton producing devices (including compact cyclotrons) the production of 
proton therapy facilities is increasing in the United States (Smith 2009). With an 
increasing number of institutions offering proton therapy, the number of multi-
institutional clinical trials involving proton therapy will also increase in the coming years.  
The National Cancer Institute (NCI) sponsors clinical trials which are opened to 
participation at multiple institutions in the country. This allows for a larger number of 
patients to be enrolled in the different protocols. The mission of the Radiological Physics 
Center (RPC) is to assure the NCI and cooperative groups that the institutions 
participating in these clinical trials are delivering comparable and consistent doses of 
radiation (Followill et al. 2007). The RPC is able to monitor sites involved in clinical 
trials through the use of site visits and remote auditing with TLD and mailable 
heterogeneous phantoms. Currently, there are no heterogeneous phantoms that have been 
commissioned to evaluate proton therapy. The RPC does have a pelvis phantom which is 
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used to evaluate intensity-modulated radiation therapy (IMRT). The purpose of this study 
is to investigate the use of the current pelvis phantom for the evaluation of the treatment 
procedures at facilities using proton therapy. 
1.2 Proton Therapy 
1.2.1    History 
 Proton therapy is a specialized radiation therapy using charged particles (protons) 
to treat tumors. Robert Wilson first hypothesized that the physical properties of protons 
could be therapeutically advantageous (Wilson 1946). In Wilson’s paper, he described 
how protons would traverse through the tissue in a nearly straight trajectory and deposit 
the majority of their dose near the distal end of their range. He also described a device 
which modulates the high dose at the end of the range to spread a uniform dose over a 
specified target volume. The first patient treatment in the US using high energy protons 
occurred at the University of California, Berkeley in 1954, only 8 years after Robert 
Wilson published his paper (Wilson 1946). The patients were treated with high-dose 
proton therapy to the pituitary following experiments involving mice and rats (Lawrence 
1957); (Tobias et al. 1958). The Harvard University Cyclotron Laboratory began treating 
patients in 1961 for intracranial cancer due to advantages over full-penetration methods. 
Noted among the reasons were the increased points of possible beam entry since the  
characteristics of protons allowed for the avoidance of radio-sensitive structures such as 
the eyes (Kjellberg et al. 1962). 
 Modern proton therapy in the US began in 1990 at the Loma Linda University 
Medical Center (LLUMC) (Slater et al. 1992). This was also the first hospital-based 
proton facility in the United States designed specifically for medical treatments. All 
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previous US facilities began as research machines. The first treatment was an ocular 
melanoma which was followed by brain tumors and other anatomical sites with the year 
(Slater et al. 1992). 
1.2.2 Physical Properties  of Protons 
Proton therapy is an exceptional form of radiation therapy due to its range and 
depth dose distribution properties. The dose from protons demonstrates a relatively 
uniform plateau region followed by a peak of maximum deposition at the end of the 
range. 
 
Figure 1.1: Comparisons of Depth Dose Distributions   
 
 Figure 1.1 is a comparison of the depth distributions for a 6 MV photon beam, a 
pristine 250 MeV proton beam and a modulated 250 MeV proton beam. The entrance 
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dose for the pristine proton beam is less than that of the photon beam and both proton 
beams have a finite range near the 26 cm mark. The photon beam continues past the end 
of the graph in what is called an exit dose. The region before the 100% dose region for 
the proton beam is called the plateau region. For the modulated proton beam, the dose in 
the plateau region is higher than the pristine beam. This is due to the modulation 
techniques of the pristine Bragg peak which is discussed in more detail in Section 1.2.5. 
The flat dose region at 100% of the dose in the modulated proton beam is the Spread Out 
Bragg Peak (SOBP).  With the proton distributions, the dose then falls off to zero very 
rapidly which gives no dose past the region which receives the highest dose. When 
carefully planned, a tumor can be fully irradiated with no exit dose.   
Protons are positively charged particles with a mass 1836 times that of an 
electron. The energy loss properties of protons allow for prediction of the range of 
protons in matter which is dependent on the initial energy of the protons and the density 
of the materials in the path of the beam. The stopping power describes the energy loss of 
protons due to interactions in matter. 
Equation 1.1 is the formula for the mass collision stopping power from the Bethe 
theory which is outlined in ICRU Report 49 (ICRU 1993). 
                       
 Lz
A
Z
u
mcrxES e 22
22
elcol
1 4dd11           Equation 1.1 
For this equation, re is the classical electron radius, mc2 is the electron rest energy, β is 
the velocity of the particle, u is the atomic mass unit, Z is the atomic number of the target 
atom, A is the atomic mass of the target, z is the charge number of the projectile while 
L(β) is the stopping number. The stopping number depends on three factors: 
1. The mean excitation energy of the medium, which quantifies the electron binding 
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energy. The mean excitation energies are usually obtained from experimental data. 
2. The shell correction accounts for the lessening contribution from the interactions with 
electrons to the stopping power as the projectile velocity decreases.  
3. The density-effect correction acknowledges that the passage of the projectile 
polarizes the medium in which the projectile is travelling. The stopping power 
reduces due to this polarization (ICRU 1993).  
 The linear energy transfer (LET) of a particle describes how the energy of the 
beam transfers to the irradiated material per unit particle path length (ICRU 2007). The 
LET can be considered a “restricted” stopping power as it does not include secondary 
collisions which result from the scattering of the particles. The LET for charged particles 
increases at the end of the track which creates what is known as the Bragg peak.   
1.2.3 Relative Biological Effectiveness 
The Relative Biological Effectiveness (RBE) describes the amount of dose from a 
radiation source needed to produce the same biological effect as a standard source of 
radiation and is described in Equation1.2 (Johns and Cunningham 1983).  
 
              
effect biological produce  tosource test from Dose
effect biological produce  tosource standard from DoseRBE        Equation1.2 
 
For proton therapy, ICRU Report 78 recommends to use a generic RBE value of 
1.1 in the clinical setting based on in-vivo laboratory studies. Along the plateau and the 
SOBP, the RBE does not show much variation until the distal end of the SOBP. At this 
location, the RBE might increase from 5-10% which can extend the biologically effective 
range of the beam by 1-2 mm (ICRU 2007).  
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Many institutions use the nomenclature “cobalt-gray equivalent” or CGE to report 
the equivalent dose of protons as compared to therapies with an RBE value of unity. This 
practice is not considered an SI unit and as such the recommended nomenclature is to use 
the RBE-weighted absorbed dose which is represented by DRBE (seen in Equation 1.3) 
where D is the proton absorbed dose (in Gy) (ICRU 2007). 
 
                                                           D1.1DRBE                                         Equation 1.3 
 
In order to distinguish between D and DRBE, when recording dose levels the 
notations of “Gy” and “GyRBE” will be used. For example, to describe the dose to the 
TLD in the pelvis phantom it will be denoted the TLD was irradiated to 6 Gy or to 6.6 
GyRBE. 
1.2.4 Proton Range 
The path length of protons is determined by the energy loss of the protons as they 
traverse through the target material. This can be determined based on the initial energy of 
the proton and the material present in the path of the beam. As the beam passes through 
material, energy is lost due to a scattering event. Since each individual particle does not 
lose the same amount of energy with each interaction, the individual path lengths of each 
particle will differ slightly. This is called range straggling and can introduce a range 
uncertainty of about 1% (Breuer and Smit 2000). Along with the uncertainty of the initial 
energy of the beam as it leaves the nozzle (~1%) and the uncertainty attributed to the 
beam passing through inhomogeneities in the beam path the total range uncertainty can 
be on the order of 2-3% (Breuer and Smit 2000). During treatment planning for a tumor 
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site, this uncertainty must be taken into account to ensure the entire primary target 
volume (PTV) is covered. 
The lateral penumbra of a proton beam is initially very sharp due to the relatively 
low amount of side-scatter when compared to more conventional radiotherapies. As 
protons penetrate through a target, the protons spread laterally primarily due to scattering. 
The range of the secondary electrons is typically on the order of 0.1 cm in organic 
material (Breuer and Smit 2000). The sharp lateral penumbra of high energy beams at 
shallow depths provides separation between the high dose target and the low dose normal 
tissues and can serve as a deciding factor for the use of proton therapy when treating near 
critical structures (Moyers 1999). 
1.2.5 Beam Modification 
 
As the proton beam enters the nozzle, several modifications are made to enable 
the use of the beam for treatment. In a passive beam, a single- or double-scattering 
technique can be used. A diagram showing the nozzle components for the passively 
scattered beam lines at the Proton Therapy center in Houston is shown in Figure 1.2 
(Sahoo et al. 2008).  
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Figure 1.2: Schematic of Nozzle Components 
 
Scattering the beam broadens the beam laterally to provide coverage across the 
treatment field. Protons exiting the first scatterer will have a Gaussian shaped intensity 
profile. As this is a non-uniform beam, a second scatterer placed downstream from the 
first is shaped to correct this Gaussian profile in order to create a uniform range across 
the axis of the beam. The lateral penumbra of the beam will broaden due to the increased 
amount of scatter in the beam path and should be reduced as much as possible to protect 
surrounding critical structures. 
A pristine Bragg peak is not large enough to adequately cover a tumor site. The 
Bragg peak must be modulated in order to produce what is called a Spread Out Bragg 
Peak (SOBP). The summation of many pristine distributions consisting of various 
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energies will produce an extended uniform Bragg peak. The SOBP will ensure the beam 
covers the depth of the tumor longitudinally. 
There are two main ways to position the Bragg peak within a patient. One way is 
to change the energy of the beam. This will accelerate or decelerate the protons allowing 
for the range to increase or decrease accordingly. The other way to position the Bragg 
peak is to introduce material in the beam path upstream from the patient. This will 
degrade the energy of the protons before they enter the patient and shorten the depth of 
beam penetration in the patient. Introducing material in the beam path is the most 
common way the Bragg peak is influenced in a clinical setting. The range shifter is 
comprised of slabs of materials with known water equivalent thicknesses (WET) that are 
placed downstream from the second scatterer and upstream from the patient apertures and 
compensators. These shifters enable the operator to move the distal end of the SOBP 
towards the nozzle dependent on the amount of water equivalent material placed 
upstream of the target. 
The range modulation wheel (RMW) is a device first described by Robert Wilson 
and expanded upon by Koehler et al (Wilson 1946; Koehler et al. 1975).  The RMW is a 
device which has staircases of materials that form two to three peaks (depending on the 
design of the wheel) which is programmed to spin quickly. An example of a RMW is 
shown in Figure 1.3. 
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            Figure 1.3: Range Modulation Wheel 
 
 By controlling the location on the wheel where the beam starts and stops, the 
depths at which pristine Bragg peaks are located can be influenced. The summation of the 
multiple Bragg peaks creates the SOBP.  
 Once the energy and SOBP for the treatment have been selected, patient specific 
apertures and compensators are constructed according to the treatment plan. The brass 
apertures (Figure 1.4) collimate the beam to conform to the treatment field.  
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Figure 1.4: Circular Aperture 
 
The collimation of the proton field by the patient specific apertures should be 
placed as close to the patient as possible due to multiple coulombic scattering in the air 
and the compensator as well as the projection of the effective source size (Moyers 1999). 
For this reason, the snout at the end of the nozzle is able to extend to be closer to the 
patient surface. 
After the apertures, a compensator (seen in Figure 1.5) is placed on the snout to 
distribute the dose deposition according to the treatment plan.  
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Figure 1.5: Compensator 
 
The compensator design matches the distal edge of the SOBP to the distal side of the 
target, and corrects for heterogeneities in the patient and uncertainties in patient 
positioning (Moyers 1999). 
1.3 Pelvis Phantom 
The RPC has several anthropomorphic phantoms which are used as part of the 
credentialing services for participation in NCI sponsored clinical trials. The pelvis 
phantom was originally designed to be a mailable quality assurance phantom to test 
intensity-modulated radiation therapy (IMRT) procedures. With this in mind, the design 
and materials were chosen to simulate the pelvis region of a patient with anatomy present 
to create restrictions for the treatment planning and delivery in typical IMRT cases. 
1.3.1 Phantom Design 
 The pelvis phantom was originally designed to be a remote auditing tool for 
institutions utilizing IMRT treatment plans in protocols. The phantom needed to be 
anatomically relevant with materials that were photon equivalent, durable enough to 
withstand constant shipping and also light weight to keep shipping costs at a reasonable 
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rate. The solution was to have a phantom that would be filled with water upon arrival at 
an institution. The phantom can be seen in Figure 1.6 and Figure 1.7. The green and blue 
knobs seen in both figures hold thermoluminescent dosimeter (TLD) capsules 
(Quantaflux, LLC, Dayton Ohio) in each femoral head while the other two knobs are the 
openings to fill and drain the water. The white region in the center is the front face of the 
dosimetry insert. 
 
Figure 1.6: Side view Pelvis Phantom 
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Figure 1.7: Inferior view Pelvis Phantom 
 
 The phantom has two removable inserts: an imaging insert and a dosimetry insert. 
The imaging insert (seen in Figure 1.8) is a hollow shell which holds two spheres 
representing the bladder and prostate (also known as the “target” for this phantom) as 
well as a cylinder which represents the rectum. The femoral heads are located within the 
shell of the patient. 
Prostate RectumBladder
   
Figure 1.8: Pelvis Phantom  Imaging Insert   
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 Figure 1.9 is an axial slice of the phantom containing the imaging insert that is 
intended for use with treatment planning. The locations where the film and TLD are 
placed during treatment delivery are overlaid onto the image, but are not seen during CT 
simulation or treatment planning. 
 
Figure 1.9: Axial CT Slice of Pelvis Phantom 
 
 The phantom materials were chosen for their equivalency based upon electron 
density and are shown in Table 1.1 (Radford 2001).   
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Material 
Material 
Density 
Material CT 
Number 
Patient CT 
Number 
Nylon - Prostate 1.15 1088 1026 
PVC - Shell 1.37 1760 ---- 
PBT - Bone 1.31 1203 1297 
HI Polystyrene - 
Dosimetry Insert 
1.20 974 ---- 
Polyethylene - 
Bladder 
0.95 923 1001 
Acrylic - Bone 
Marrow 
1.17 1123 ---- 
Wax - Rectum 
1.00 950 922 
Table 1.1: Phantom Materials Comparison with CT Values 
 
 Once the treatment plan was completed, the dosimetry insert (shown in Figure 
1.10 ) replaced the imaging insert.  
 
Figure 1.10:  Pelvis Phantom Dosimetry Insert 
 
This solid insert holds two TLD capsules and two pieces of radiochromic film in the 
orientation displayed in Figure 1.9. Two more TLD capsules are placed in the femoral 
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heads prior to irradiation. Solid acrylic rods are used during CT simulation. 
1.3.2 Phantom Use in Credentialing 
The phantoms used by the RPC are intended to measure the quality of the overall 
treatment procedure for institutions participating in clinical trials. Quality assurance for 
dose calculation and treatment verification can be difficult for advanced treatment 
procedures. Proton therapy dose calculations are dependent on accurate simulations and 
precise treatment setup to correctly deliver the intended treatment. Having a phantom 
which mimics patient anatomy challenges the treatment planning process and requires a 
realistic dose calculation for a patient treatment. Using the same phantom from treatment 
planning for treatment delivery tests the institution’s procedures for re-creating the 
patient setup from the initial CT scan. This phantom should audit the accuracy of the CT 
simulation, challenge the treatment planning system and provide dose measurements for 
treatment delivery. 
1.4 Hypothesis and Specific Aims 
 An anthropomorphic pelvis phantom can be designed to audit treatment 
procedures (patient simulation, treatment planning and treatment delivery) at proton 
facilities to confirm agreement between the measured dose and calculated dose within 
5%/3mm with a reproducibility of 3%.  
 The hypothesis was tested through the completion of the specific aims listed 
below. The phantom was simulated, planned and treated to emulate a prostate treatment 
with proton therapy. Modifications were made throughout the process and the specific 
aims were reapplied as the phantom was evaluated using the agreements listed in the 
hypothesis. The specific aims were: 
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1) Determine the equivalency of phantom materials to their patient anatomy 
counterparts. 
2) Image the pelvis phantom, create a clinically relevant treatment plan, and irradiate 
the phantom with this treatment plan. 
3) Measure the delivered dose distribution and the dose to specific points within the 
irradiated pelvis phantom. 
4) Compare the calculated and measured doses and dose distributions to determine 
the deviations and reproducibility. 
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Chapter 2 
Materials and Methods 
2.1 Phantom Material Stopping Powers 
 The range of protons is determined by the initial energy of the proton beam and 
the materials placed in the path of the beam. The relative stopping power and width of 
each piece of material in the path of the beam defines where the Bragg peak will occur.  
The materials incorporated in the phantom were chosen due to their photon equivalency 
and the individual stopping powers were not investigated in the original design of the 
phantom. For this study, the relative stopping power of each phantom material was 
measured to validate the overall composition of the pelvis phantom. 
2.1.1 Depth Dose Scanning Procedure 
 A portable in-house RPC water phantom was used to take depth dose 
measurements at the University of Texas M.D. Anderson Cancer Center Proton Therapy 
Center – Houston (PTC-H). An Exradin P11 parallel plate chamber (Standard Imaging, 
Middleton, WI) was used as the primary scanning chamber with an Exradin A12 thimble 
chamber (Standard Imaging, Middleton, WI) as a reference. The gantry was set at 270º 
with a source-to-axis distance of 270 cm set to the inside of the window of the water 
phantom.  
Equation 2.1 is a way to measure relative stopping powers of materials to that of 
water (Schaffner and Pedroni 1998). This equation was used to measure the relative 
stopping powers of each material used in the phantom where Δx is the shift in the percent 
depth dose (PDD) curve when the target material is placed in the path of the beam. The 
reference curve was taken with no phantom material placed in the beam path.   
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material ofwidth 
1Power Stopping Rel x                       Equation 2.1 
 
The sample materials were taken from the same batch used to build the pelvis phantom. 
This insures that the overall composition and density of the samples match the structures 
used to create the phantom. Each material width was measured with calipers at four 
separate locations. These were averaged for the width used in Equation 2.1.  
 The reference curve (with no phantom material in the path of the beam) was 
produced with a 250 MeV beam energy, range shifters for a 10 cm range and a 5 cm 
modulation. A phantom material was secured to the front window of the water phantom 
without changing any delivery conditions as seen in Figure 2.1. The same beam 
conditions were used to produce a modified percent depth dose curve and the phantom 
material was replaced. This procedure was repeated until each material had been placed 
in the path of the beam. A second reference curve was taken at the end of session to 
ensure the beam output and setup conditions had not changed during the course of 
measurements.  
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Figure 2.1: Stopping Power Measurement Setup 
 
2.1.2 Relative Stopping Power Analysis 
Each percent depth dose curve was first normalized by using the average value of 
5 points centered at the nominal center of the Spread-Out Bragg Peak (SOBP) as the 
maximum value. Excluding the reference curve, each modified PDD curve was shifted by 
the width of the material placed in the path of the beam. The conditions to correctly 
utilize Equation 1 involved placing the materials inside the water phantom. By adding the 
material width to the corresponding modified PDD, the starting depth was corrected to 
account for placing the materials outside of the water phantom. A cubic spline 
interpolation was performed to estimate the value at the distal 90% for each curve. ∆x 
was computed from the difference between the values for the material and the first 
reference curve. The appropriate values were then used in Equation 2.1 to calculate the 
relative stopping power for each material.  
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2.1.3 Relative Stopping Power Comparison 
 The PTC-H uses the Eclipse treatment planning system (TPS) (Varian Medical 
Systems, Palo Alto, CA) to create patient treatment plans. The TPS contains a calibration 
curve which converts the Hounsfield Units (HU) from the CT scanner to the relative 
stopping powers of human tissues. HU for each material were measured to compare with 
the values that are assigned by Eclipse. 
 A CT scan of the pelvis phantom (discussed in more detail in Section 2.2) was 
uploaded into Eclipse. Eight points taken across each structure and the dosimetry insert 
were averaged together to determine the HU for each phantom material. With the 
phantom material HU values, the measured relative stopping powers were plotted on the 
TPS calibration curve for comparison. Values taken from the literature  for the phantom 
materials (Schneider et al. 1996) were also compared using the Eclipse HU values except 
for the PBT and High Impact Polystyrene. Literature values for these two materials were 
not found. 
 The relative stopping power comparisons were made to validate the use of the 
pelvis phantom in proton beams and to predict sources of discrepancies between 
treatment planning and treatment delivery. By comparing the measured stopping powers 
to the stopping powers found in the literature, it could be determined if the calculations 
were done correctly. 
2.2 Treatment Planning 
The purpose of the pelvis phantom is to evaluate the entire proton treatment 
process. With this in mind, all efforts were made to keep treatment planning as close to a 
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patient plan as possible. The phantom shell and imaging insert were both filled with 
room-temperature water and a special effort was made to minimize the capture of air 
bubbles within the phantom. The dosimetry insert was loaded with TLD and film for 
imaging purposes. The phantom was placed on the CT table and the laser markings were 
drawn on the left and right lateral surfaces as well as the anterior surface of the phantom 
for reference during treatment delivery setup. Small plastic BBs were placed on the laser 
markings to localize the phantom’s position in the TPS. The pelvis phantom was scanned 
twice on a GE LightSpeed RT16 CT scanner at the PTC-H using the pre-set abdomen 
protocol. This first scan had the imaging insert loaded in the phantom and the second 
scan had the dosimetry insert loaded in the phantom. Once the images had been moved to 
the Eclipse treatment planning system the BBs were physically removed from the 
phantom while the laser markings were left in place. The BBs would have added material 
to the beam path and changed the delivered treatment from the planned treatment. Two 
separate treatment plans were designed from the acquired images.  
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Figure 2.2: Screen capture from TPS 
 
2.2.1 Treatment Plan 1  
 For the first treatment plan, the relative stopping powers assigned by Eclipse were 
used to calculate the dose distribution. The outer shell was contoured such that the BBs 
were not included in any dose calculations. The image set with the imaging insert was 
used for the main treatment plan as it held the necessary anatomy. The prostate, bladder, 
rectum and femoral heads were all contoured separately. Two lateral beams were placed 
so that the summed SOBPs formed a box surrounding the prostate using a preset beam 
template that is used for the majority of prostate treatments.  
 Figure 2.2 shows the pelvis phantom while being planned in Eclipse. The top left 
image is an axial view of the phantom with contoured structures with isodose lines 
surrounding the prostate. The coronal and sagittal views are on the bottom while the top 
right image shows the apertures on either side of the phantom. 
The plan was approved for treatment by a radiation oncologist and the dose scaled 
 25  
to deliver 600 cGyRBE to the prostate. Points of interest were placed in the center of the 
target and at the location of the TLDs in each femoral head and the TPS was used to 
calculate the expected dose at each point of interest. The TPS was also instructed to 
design apertures and compensators for the two beams in Plan 1 and the information was 
transferred to the machine shop for construction. The beam parameters calculated by the 
TPS are displayed in Table 2.1 
 
 
 
 
Beam Parameters - Plan 1 
Prescribed Dose - 600 cGyRBE 
   Left Lateral  Right Lateral 
Nominal Energy  250 MeV  250 MeV 
SAD  270 cm  270 cm 
Field Size  18 cm x 18 cm  18 cm x 18 cm 
Gantry Angle   90º  270º 
Nominal SOBP  8 cm  8 cm 
Planned Distal 
Target Distance 
 24.1 cm 
 
23.9 cm 
Air Gap  10.8 cm  10.8 cm 
Snout Position  30 cm  30 cm 
Range Modulator  RM_27  RM_27 
Isocenter Dose  299.5 cGyRBE  300.8 cGyRBE 
Isocenter Depth  18.5 cm  18.6 cm 
Isocenter Eq. 
Path Length 
 19.6 cm 
 
19.7 cm 
Table 2.1: Beam Parameters for Treatment Plan 1  
 
 26  
 The insert used to create the treatment plan and the insert used to hold the TLD 
and film are composed of different materials which could cause the measured dose to 
differ from the expected dose. To evaluate this dose difference, the CT scan of the pelvis 
phantom (discussed in Section 2.2) with the dosimetry insert was uploaded into 
Treatment Plan 1 as a “verification plan”. The proton fluence, apertures and 
compensators from the beams used for the original plan were copied into this verification 
plan and the dose from the beams incident on the dosimetry insert was calculated. The 
same dose points were placed on the verification plan to compare the calculated dose to 
the measured TLD dose. 
 
2.2.2 Treatment Plan 2 - New SP Plan 
 For the second treatment plan, the measured stopping powers were substituted for 
the values assigned by the HU-Stopping Power calibration curve. This can be done by 
selecting a contoured organ and reassigning the Hounsfield Unit in Eclipse. A linear 
interpolation was performed to find the corresponding HU number for each measured 
stopping power. A new plan was created to deliver 600 cGyRBE to the prostate. The same 
points of interest from Treatment Plan 1 were placed on Treatment Plan 2. The new 
aperture and compensator designs were transferred to the machine shop to be built. The 
same beams and points of interest were placed on the dosimetry insert to calculate the 
expected dose at the locations of the TLD in the same manner as with Treatment Plan 1. 
The beam parameters for Treatment Plan 2 are listed in Table 2.2. 
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Beam Parameters - Plan 2 - New SP Plan 
Prescribed Dose - 600 cGyRBE 
   Left Lateral  Right Lateral 
Nominal Energy  250 MeV  250 MeV 
SAD  270 cm  270 cm 
Field Size  18 cm x 18 cm  18 cm x 18 cm 
Gantry Angle   90º  270º 
Nominal SOBP  9 cm  9 cm 
Planned Distal 
Target Distance 
 25.0 cm 
 
24.8 cm 
Air Gap  10.2 cm  10.3 cm 
Snout Position  30 cm  30 cm 
Range Modulator  RM_27  RM_27 
Isocenter Dose  299.5 cGyRBE  300.7 cGyRBE 
Isocenter Depth  18.5 cm  18.6 cm 
Isocenter Eq. 
Path Length 
 20.1 cm 
 
20.3 cm 
Table 2.2: Beam Parameters for Treatment Plan 2 – New SP Plan 
 
 The effort was made to keep as many parameters between Plans 1 and 2 identical 
so the differences in results could be attributed to the difference in relative stopping 
power values used to calculate dose. 
2.3 Dosimeters 
The two dosimetry tools used with the phantom during irradiation are TLD 
capsules and Gafchromic® film. The TLD was used as an absolute dosimeter to measure 
point doses in specific locations. The film dose was scaled relative to the TLD dose to 
provide two-dimensional profiles across the sagittal and coronal planes of the phantom. 
2.3.1 EBT Film 
Gafchromic® EBT film was used to gather data along the coronal and sagittal 
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planes. Film is a being a 2-D dosimeter and is able to gather spatial information as 
compared to TLD. The film is a light blue which darkens in the presence of radiation but 
is insensitive to room lighting. Figure 2.4 shows the layers used to compose the film from 
the white paper published for this film (ISP 2007). 
 
Clear Polyester                 97 microns 
Active layer                      17 microns 
Surface Layer                    6 microns 
Active layer                     17 microns 
Clear Polyester                  97 microns 
 
Figure 2.3: Configuration of the Gafchromic® EBT Film  
 
The effective atomic energy of the film is 6.98 (ISP 2007) making it close to 
tissue equivalent in a photon beam and an appropriate addition to the current pelvis 
phantom. The optical density of the exposed film is proportional to the dose to the film 
and it has been found that the response for Gafchromic® MD-55 film is nearly linear 
from 0 – 100 Gy in proton beams (Vatnitsky 1997). It is expected that the Gafchromic® 
EBT film has a similar response. The relative stopping power of the film was not 
measured in this study. The MD-55 film has also been found to be independent of 
energy within each batch and calibration curves created using 60Co radiation, high-
energy electrons and protons were observed to be near identical in this study (Vatnitsky 
1997). It has also been shown that the calibration of EBT film using a 6 MV photon 
beam is within 2.5%  of a calibration in a proton beam at 5 and 10 Gy (Nerbun 2005). 
Since the film is being used a relative dosimeter, it was decided that use of the 
calibration curve from a photon beam was an appropriate decision. 
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Pieces of Gafchromic® EBT film Lot # 48022-05I (ISP Technologies, Wayne, 
NJ) were cut to fit in the coronal and sagittal planes of the dosimetry insert. The films 
were kept in black envelopes labeled by plan and trial. The films were labeled prior to 
irradiation for orientation purposes. The films from each trial were all cut from the same 
piece of film and all film irradiations were made using the same batch of film. The TLD 
were also from the same batch and were identified by plan, trial and location within the 
phantom. 
 
Figure 2.4: Dosimetry Insert 
 
2.3.2 Thermoluminescent Dosimeters  
 For this project, capsules containing LiF TLD-100 powder were used to take 
absolute point measurements within the phantom. These pre-loaded capsules contain 
about 22 mg of powder. Double loaded capsules contain two pockets of TLD powder 
each with about 22 mg of powder. The double loaded capsules were used for TLD 
measurements. 
 In thermoluminescent (TL) detectors, incident radiation releases electrons from 
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the valence band to the conduction band and the electrons are then captured by various 
trapping centers (Knoll 2000). When exposed to heat, these trapped electrons are able to 
return to the conduction band while releasing light. A photomultiplier tube (PMT) can 
record the amount of light and a glow curve is produced comparing the light signal to the 
temperature at the time of light emission. The glow curve will have several peaks 
corresponding to the different trapping centers. The low temperature energy traps are not 
stable at room temperature and are susceptible to spontaneous recombination. The TL 
signal for these peaks are not reliable. By waiting to read out the TLD (usually for 10-14 
days) and pre-heating the crystal, the low temperature traps are cleared leaving the stable 
high temperature traps which provide useful signal. The TL signal is the area under the 
glow curve which corresponds to the number of photons released. This signal, along with 
the correction factors listed in Equation 2.2 yields the dose delivered to the TLD. 
 
                                 S  K K  K T D fle                            Equation 2.2 
 
Equation 1.4 outlines the procedure for measuring the absorbed dose, D, given to the 
TLD where T is the TL signal divided by the mass of the aliquot of powder, Ke is the 
energy correction, Kl is the linearity correction, Kf is the fading correction and S is the 
system sensitivity. The K factors are consistent throughout each batch of TLD and only 
need to be found when initially characterizing the current batch. As the RPC conducts 
large scale remote auditing, having the same correction factors reduces the time needed to 
evaluate irradiated TLD. 
 The energy correction factor accounts for the difference of the TLD response in 
energies other than the standard 60Co used to commission the TLD batch. This factor is 
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determined by comparing the dose response of TLD in a specific beam to the response of 
TLD in 60Co beam for the same absorbed dose (Kirby et al. 1992).   
 The linearity correction factor accounts for the supra-linearity response of the 
TLD batch over a range of 0-6 Gy. TLD capsules are irradiated over the designated range 
and a least squares fit is applied to the data set of reading versus dose. Kl is described by 
Equation 2.3.  
                              bmKl  dose raw                                          Equation 2.3    
        
In this equation, the raw dose is the TL reading per mg corrected for system sensitivity 
and fading, and both m and b are parameters which are batch specific. 
 The fading of the TL signal is another batch-specific quantity and is measured 
over time. Equation 2.4 is fitted to the measured data with the quantities a, b, c, d, and N 
all being batch specific parameters and X being the time in days from irradiation. 
                                            dXbXf eceaNK   /                                 Equation 2.4 
 
The TLD used in the pelvis phantom was read out at a minimum of 10 days post-
irradiation to reduce the fading effect. 
 The system sensitivity can change for every readout session due to factors 
including (but not limited to) the electronics of the reader, heater characteristics and 
planchet reflectivity (Kirby et al. 1992). This factor, S, is determined by Equation 2.5 
where the “prime” values are for the “standard” TLD. The standard TLD are irradiated to 
a known dose determined by an ionization chamber measurement. 
                                                 '''' lf KKTDS                                        Equation 2.5 
 
The standard TLDs are read out at the beginning and end of each session so the correct S 
 32  
value can be interpolated for any reading during the session and applied in Equation 2.2. 
Four TLD-100 capsules (Quantaflux, LLC, Dayton Ohio) were placed within the 
pelvis phantom for each irradiation. Two TLD capsules were in the center of the 
dosimetry insert in the same location in space as the center of the prostate and one TLD 
capsule was placed in each femoral head in the same plane as the target TLD. The film 
was placed in the dosimetry insert (as seen in Figure 2.4) and was held in place by small 
pins. The coronal film is one solid piece while the sagittal film is cut in half to intersect at 
the center of the insert. The two TLD capsules fit in the center of the insert near the 
cross-section of the film. 
 
 
Figure 2.5: Phantom Treatment Setup 
 
2.4 Treatment Delivery 
 Once the pelvis phantom was loaded with the film and TLD, the phantom was 
placed on the treatment table. With the gantry rotated to 270º the lasers were turned on to 
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set the phantom to the laser markings drawn during simulation. The lasers were used to 
verify the phantom’s positioning between each trial to correct any movement while 
inserting new TLD and film. The beam parameters (listed in Tables 2.1 and 2.2) and the 
monitor units were entered into the computer console for beam delivery. Each treatment 
was performed with two fields in one fraction. For each treatment plan, 3 irradiations 
were made using the pelvis phantom. 
 
2.4.1 Monitor Unit Calculation  
 The monitor units (MU) for each beam were entered into the console for the 
simplest delivery of the two treatment plans. The record and verify system was not used 
to expedite treatment delivery. The plan was prescribed to deliver 600 cGyRBE but the 
goal was to deliver a dose of 600 cGy to the TLD at the target. For 600 cGy to be 
delivered to the TLD at the target, the monitor units were calculated to deliver 660 
cGyRBE to account for the clinical relative biological effectiveness value of 1.1 for proton 
therapy.  
 The monitor unit calculation at the PTC-H utilizes several factors including a 
relative output factor, range shifter factor, spread out Bragg peak factor, and an inverse 
square factor (Sahoo et al. 2008). Any change from the reference conditions listed in 
Table 2.3, produces a change in the respective output factor. The machine is calibrated 
using the IAEA TRS 398 protocol (Andreo et al. 2000). These factors can be found in 
reference tables created from data taken during commissioning.  
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Energy 250 MeV 
Range 28.5 cm 
SOBP 10 cm 
Range Shifter none 
SDD 270 cm 
Table 2.3: Dosimetry Reference Conditions 
 
Equation 2.6 was used to calculate the monitor units for treatment 
         
OCF SOBP Factor  Comp. ISQ Factor  SOBP Factor Shifter  Range  OF Rel.
cGy)PointDose(MU    
                                                                                                                          Equation 2.6 
 
where Rel. OF refers to the relative output factor, ISQ refers to the inverse square factor, 
Comp. Factor refers to the compensator factor and SOBP OFC refers to the SOBP off-
center factor. The aperture factor was not considered in the calculated MU; however, the 
dependence of output on aperture size is known to be very small and this omission was 
shown to contribute less than a 1% error to the total calculation. 
2.5 Dosimetry Data Analysis 
 The two dosimetry tools with the phantom during irradiation are TLD capsules 
and Gafchromic® film as mentioned in Section 2.3. The TLD was used as described in 
Chapter 1 to determine point doses in specific locations. The film dose was scaled 
relative to the TLD dose to provide two dimensional profiles across the sagittal and 
coronal planes of the phantom. 
2.5.1 TLD Registration 
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 The dimensions of phantom insert were measured from the CT scan of the 
phantom. Five points on the imaging insert were chosen: the superior edge of the target, 
the posterior edge of the rectum, the center of the target, the right edge of the target and 
the inferior edge of the target. The center coordinates were designated as (0,0,0). From 
the center of the physical insert, the coordinates of the TLD were measured. All of the 
coordinates were recorded in a spreadsheet which is uploaded into CERR (Deasy et al. 
2003). Once the treatment plan is uploaded to CERR, the registration can be performed 
using the 5 points described above. Once registered, the position of the measured dose 
from the TLD can be correlated with the dose profiles from the TPS.  
2.5.2 Film Dosimetry 
 The EBT film was cut to fit in the phantom with one piece of film through the 
coronal plane and two smaller pieces through the sagittal plane. The CT scan of the 
phantom with the film-loaded dosimetry insert in place was used to check for any air 
gaps along the planes of the film.  Extra pieces of film were fitted in the dosimetry insert 
to try and eliminate these air gaps. 
 The film was calibrated with a Varian 2100 linear accelerator (Varian Medical 
Systems, Palo Alto, CA). One piece of film was cut into 9 smaller square pieces of film 
and irradiated at 9 levels ranging from 50-1350 MU. This was done using 6 MV photons, 
a 35 cm x 35 cm field size and an output factor of 1.075 giving doses which ranged from 
53.75 cGy to 1451.25 cGy.  Each piece of film was pre-labeled to preserve orientation 
and to later identify the dose given to each individual cutout. The film was scanned with 
a CCD Microdensitometer for Radiochromic Film Model CCD100 (Photoelectron 
Corporation, Lexington, MA). A background film from this batch of film was used to 
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acquire a flat field image and a grid with 1 cm blocks was used for spatial calibration of 
the system. Using these two corrections, the film was placed in the densitometer and the 
images were saved as FIT files for later evaluation. 
 The average optical density of each piece of the calibration film was measured 
with ImageJ software (Rasband 1997-2009). A calibration curve to convert optical 
density into dose was created for each of the 3 trials and a cubic polynomial fit was 
applied. This fit was used to convert the films from the pelvis phantom into dose 
measurements. Error bars reflecting the standard deviations of the dose values were 
placed on the calibration curves for comparison between the trials. Any points outside of 
the corresponding error bars from the other two calibration curves would raise a concern 
about the film’s irradiation and subsequent analysis. 
2.5.3 Film Registration 
To register the position of the film to the TPS, four pin pricks were placed on 
each film. These pins were inset in the dosimetry insert and were also used to hold the 
film in place. A template was created for the pin pricks for each plane of the film and the 
coordinates of each pin were recorded in a table. These data were stored in a spreadsheet 
that was recalled when registering the film in an in-house program which supplements 
CERR. This software also included a section to place the TLD measurements and would 
automatically scale the film dose to these points. The pin holes in the scanned film were 
carefully selected and then uploaded into CERR for registration with the TPS. The dose 
profiles from film were compared to the treatment plan to check for agreement in the 
dose surrounding the prostate. The profiles were taken through the center of the coronal 
plan from left to right and from superior to inferior. The sagittal profiles went through the 
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center of the film in the AP PA direction and were off-center 2 mm from superior to 
inferior. This was due to the sagittal film being cut in the center to intersect with the 
coronal film. These selected dose profiles through the film and TPS are exported for 
further analysis as discussed in Section 2.6.2. 
2.6 Treatment Procedure Evaluation 
2.6.1 TLD Comparison 
The TLD for the phantom measurements were read out 14 days post irradiation 
for Plan 1 and 10 days post irradiation for Plan 2. The readings were inserted in an Excel 
worksheet which accounts for all of the correction factors listed in Equation 2. The 
measured value was directly compared to the expected dose at the corresponding point 
from the TPS for a ratio. For Plan 1, this was done for the main plan on the imaging 
insert and the verification plan for the dosimetry insert so the two inserts could be 
compared. A ratio value from 0.95 – 1.05 was considered a passing value. The TLD for 
each plan were also evaluated for reproducibility using the coefficient of variation (COV) 
and a value no greater than 3% was considered a passing value.  
A one-sample t-test was also performed on the TLD data to check for statistical 
significance with α = 0.05 as the significance level. The null hypothesis, μ0, was defined 
to be equal to 0.949 and corresponds to the null hypothesis in Equation 2.7. The 
hypothesis proposed earlier required μ > 0.949. The standard deviation, s, the total 
number of values, n, and the mean for the three trials, x , were also used to calculate the 
t-test (Rosner 2006).                               
                                                   
ns
xt 0                                          Equation 2.7 
 
The Excel function TDIST was utilized to calculate the corresponding p-value. 
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The p-value needed to be less than 0.05 for statistical significance. If the p-value was 
greater than 0.05, then the results would not be considered statistically significant and the 
null hypothesis would be accepted (Rosner 2006). 
2.6.2 Beam Profiles Comparison 
To evaluate the accuracy of the treatment delivery, the beam profiles from the 
film were compared to the corresponding beam profiles from the TPS. These profiles 
were exported into an Excel spread sheet and plotted for visual inspection. The maximum 
and minimum dose values along the dose gradients of the film profile were used to 
determine three locations along each profile: the 75%, 50% and 25% dose points. A 
linear regression was taken over the portion defined by 80% and 20% of the profile edge 
so a formula could be derived for both the film and TPS dose profiles. The doses at the 
three previously designated points were calculated for each profile and the displacement 
between each set of doses was calculated. The average displacement for these three 
points defined the displacement between the two profiles. A displacement no greater than 
3 mm was considered as having passed.  
2.6.3 Treatment Plan 2 Quality Assurance 
 The treatment plan for the new stopping powers was also checked using the 
patient QA for normal clinical treatments. The beams from the treatment plan were 
placed in a verification plan with a water phantom in place of the pelvis phantom in the 
same manner described in Section 2.2.1. The dose profiles were calculated and a profile 
through the center of the field along the coronal plane was exported. 
 Much like the process for measuring relative stopping powers described in 
Section 2.1.1, the water phantom was set to scan along the beam. Instead of an open field, 
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the apertures created for the plan were in place. The beam parameters listed in Table 2.2 
were set and the beam was turned on for the duration of the scan. This was done for both 
fields, right and left lateral, with the gantry in the corresponding position. The water 
phantom was set to have the window facing the snout of the machine. 
The data from the scans were compared to the data from the TPS by finding the 
center of the SOBP for both scans. The scans were then compared relative to their 
respective center points and the shift of the distal 90% depth dose point was measured 
using a cubic spline interpolation in the same manner as in Section 2.1.2. Any significant 
shift between distal 90% points of the depth dose curve would indicate a difference from 
the plan to treatment. 
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Chapter 3 
Results and Discussion 
3.1 Phantom Material Stopping Powers 
3.1.1 Relative Stopping Power Analysis 
 The depth dose scan obtained with each of the materials tested attached to the 
front of the water phantom was compared with the depth dose scan obtained with the 
material removed. Figure 3.1 shows the percent depth dose curve with nylon in the beam 
(shown in blue) and the curve obtained in water (shown in pink). Nylon was the material 
used to represent the prostate. 
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Figure 3.1:  Depth Dose Curve with and without Nylon 
 
 The difference in the distal ends of the SOBP shows the difference in the 
penetration of the beam due to the difference in the stopping power of the materials in the 
beam path. The “x” placed on the distal end of the peak marks the 90% depth dose point 
as calculated from the cubic spline interpolation. Since the distal 90% of the beam is used 
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to define the end of the range for a SOBP, it was chosen as a consistent point to measure. 
The values for Equation 2.1 are listed in Table 3.1 for all of the phantom materials to 
calculate the measured relative stopping powers. 
Material Width (cm) Shift (cm) Rel. SP 
Nylon - Prostate 0.979 0.198 1.20 
PVC - Shell 0.549 0.125 1.23 
PBT - Bone 0.693 0.142 1.21 
HI Polystyrene - Dosimetry Insert 1.46 0.096 1.07 
Polyethylene - Bladder 1.05 -0.003 0.997 
Acrylic - Bone Marrow 1.67 0.353 1.21 
Wax - Rectum 2.42 0.029 1.01 
Table 3.1: Relative Stopping Powers 
 
 The measurements of the thickness of each material had an absolute error of 0.005 
mm for each side of the materials and a total error of 0.01 mm or 0.001 cm. The material 
samples were not of uniform thickness so the uncertainties of thickness for each side 
were added together for the total error. The scanning system is believed to be accurate 
within 0.1 mm giving an uncertainty for the relative SP on the order of 0.01.  
3.1.2 Stopping Power Comparison 
The stopping powers were compared to the literature values described in 
Schneider et. al. and were plotted in Figure 3.2 along with the HU calibration curve for 
the Eclipse TPS and the measured values from Table 3.1. The HU were decided using the 
procedure outlined in Section 2.1.3. 
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Figure 3.2: Comparison of Relative Stopping Powers  
 
The measured stopping powers were all less than 5% different than the corresponding 
literature values. For this reason, the measured stopping powers were considered valid as 
differences in material composition and density could account for the differences in the 
stopping powers. The measured stopping powers for several of the materials, including 
the target material, were nearly 10% different from the stopping power values used in the 
TPS. For this reason, two plans were created to quantify the differences this caused in 
phantom irradiation.   
 The difference in the stopping powers values for the phantom materials from the 
TPS could impact the comparisons of the calculated and measured dose by greatly 
affecting the measured dose. If the two treatment plans deliver significantly different 
results, it would be necessary for institutions to correct the TPS for the actual stopping 
powers of the materials. Otherwise, any failure to meet the specified requirements to pass 
the phantom evaluation could be attributed to the material stopping powers and not the 
institution’s treatment procedures. 
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3.2 Treatment Planning 
3.2.1 Treatment Plan 1 
 The TPS was used to generate a plan using the parameters that were listed in 
Table 2.1. The dose was calculated with the beams placed on both the imaging insert and 
again with the beams placed on the dosimetry insert. The results are shown in Table 3.2. 
 
Dose Points 
Calc. Dose (cGyRBE) 
Imaging Insert 
Calc. Dose (cGyRBE)  
Dosimetry Insert 
PTV Right 600.2 596.0 
PTV Left 600.2 596.0 
Right Femoral Head 247.3 249.6 
Left Femoral Head 243.8 245.2 
Table 3.2: Calculated Dose Points Plan 1 
 
The TPS automatically planned using the clinical RBE value of 1.1. To have the 
physical dose to the target be 6 Gy, the biological dose to the phantom was equal to 6.6 
cGyRBE. It is convention to irradiate the phantom TLD and film to a target dose of 6 Gy. 
Dose delivery needs to be carefully documented to correctly estimate the dose delivered 
to the TLD. 
3.2.2 Treatment Plan 2 – New SP Plan 
 The measured stopping powers used to create the second treatment plan are 
shown in Table 3.3 and are graphically represented in Figure 3.3. 
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Material CT Values Corrected 
CT Values 
Original 
Nylon - 
Prostate 376 HU 77 HU 
PVC - Shell 427 HU 800 HU 
PBT - Bone 384 HU 215 HU 
Polyethylene - 
Bladder -10 HU -34 HU 
Wax - Rectum 18 HU -80 HU 
 
Table 3.3: Plan 2 CT Values 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
-1500 -1000 -500 0 500 1000 1500 2000
 Hounsfield Units
R
el
at
iv
e 
St
op
pi
ng
 P
ow
er
s
Treatment Planning Values Phantom Values (HU-Eclipse)
Stopping Powers Literature Scaled HU for NEW SP PLAN  
Figure 3.3: Revised SP Calibration Curve 
 
Figure 3.3 shows how the measured stopping power values in pink are shifted laterally 
onto the Eclipse system’s curve depicted by the green triangles. By overriding the HU in 
the TPS, the measured SP values were instead being used to plan the treatment and to 
calculate the dose distribution. The calculated doses for the new stopping powers are 
shown below in Table 3.4. 
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Dose Points 
Calc. Dose (cGyRBE) 
Imaging Insert 
Calc. Dose (cGyRBE) 
Dosimetry Insert 
PTV Right 600.2 594.9 
PTV Left 600.2 594.9 
Femur Right 252.2 250.4 
Femur Left 248.1 247.8 
Table 3.4: Calculated Dose Points Plan 2 
 
When the dose distribution was calculated on the dosimetry insert, the dose to the PTV 
was reduced by about 1% for both plans. As the dosimetry insert is slightly denser than 
water with a larger stopping power (refer to Table 1.1 and Table 3.1), a small decrease in 
dose was expected. The change in the femoral heads was not expected since the femoral 
heads are fixed in the phantom shell and do not change with different inserts. The 
difference in the calculated doses to the femoral heads between the two inserts was again 
within 1%. This difference could be simply from a re-calculation in general (assuming 
the calculation algorithm changes minutely with every calculation) or could be caused by 
the change in the interface at the insert. 
 
3.3 Treatment Delivery 
The monitor units (MU) were calculated to deliver the treatment to the pelvis 
phantom using Equation 2.2. The exact factors and final number of MU for both plans are 
listed in Table 3.5. These factors correct for the differences between the reference 
conditions (Table 2.3) and the beam parameters for treatment (Table 2.1 and Table 2.2). 
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  Plan 1   Plan 2 - New SP Plan 
Beam Left Lateral Right Lateral   Left Lateral Right Lateral 
Relative OF 1.000 1.000   1.000 1.000 
Range Shifter Factor 0.967 0.968   0.972 0.973 
SOBP Factor 1.057 1.057   1.028 1.028 
ISQ Factor 1.000 1.000   1.001 1.000 
Compensator Factor 1.000 1.000   1.000 1.000 
SOBP OCF 1.000 0.997   1.001 0.999 
MU Required 294.3 293.6   300.3 299.7 
Table 3.5: Monitor Unit Calculation 
 
 The MU increased from Plan 1 to Plan 2 which suggests the materials in the 
phantom have higher stopping powers than the TPS calibration curve would assign. A 
difference was expected as the TPS uses a calibration curve designed for human tissue 
and not plastic material. Figure 3.3 shows the difference between the stopping powers 
used to calculate the two plans. The pink squares represent the stopping powers of the 
phantom materials at the HU assigned by the TPS. As previously mentioned in Section 
3.1.2, five of the materials have noticeably larger stopping powers than the assigned 
value (as seen by the blue line representing the TPS calibration curve).  
3.4 Dosimetry Data Analysis 
The dosimetry tools for the phantom were evaluated as a system to verify the 
treatment planning, setup and delivery to the pelvis phantom. The TLD irradiations were 
used as the absolute dosimeter and the film dose was scaled to these dose points for a 
relative measurement.  
3.4.1 Thermoluminescent Dosimeters 
 The TLD batch used in the pelvis phantom was named B07 and had been 
commissioned prior to the start of this project. Equation 2.2 listed the correction factors 
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used for the final dose calculation with Equations 2.3-2.5 detailing the quantities which 
go into these correction factors. 
 The linearity correction factor (Equation 2.3) is derived from the least-squares fit 
described in Section 2.3.2. The slope (m) for B07 was -0.00027842 and the y-intercept 
(b) was 1.08353.  The fading correction factor (Equation 2.4) was a more complicated fit 
and the batch-specific values are listed in Table 3.6. 
 
 
Table 3.6: Fading Correction Constants 
N 1.3493 
a 1.2815 
b 0.00010885 
c 0.06781 
d 0.071908 
X Days From Irradiation 
 
3.4.2 TLD Registration 
 The TLD was registered to the phantom plan through designated points that were 
measured on the CT scan set to 2 mm slice widths. The five landmarks were chosen since 
they are easily visible on the scan and are not in the same plane. Three of the points 
shown (posterior edge of the rectum, the center of the prostate and the right edge of the 
prostate) were in the same center plane while the other two points moved superior and 
posterior in the phantom. Table 3.7 lists the coordinates set from the initial CT scan 
during commissioning in millimeters while Figure 3.4 is a snapshot of the plan 
registration showing points contained in the same plane of the treatment plan. Once the 
plan was registered, the two TLD locations within the dosimetry insert were known as 
being 4 mm right posterior and 4 mm left anterior from the designated center of the 
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phantom. 
3D coordinates on Imaging Insert 
  
edge target 
superior 
edge rectum 
posterior 
center 
edge 
target right 
edge target 
inferior 
x 0 0 0 25 0 
y 0 -56.1 0 0 0 
z 25 0 0 0 -25 
Table 3.7: 3D Coordinate Registration 
 
 
Figure 3.4: Treatment Plan Registration 
 
 The registrations were evaluated by the root mean square (RMS) value of the 
differences between the known location of a point and its coordinates on the CT. For Plan 
1 the RMS was 0.87 mm and for Plan 2 – New SP the RMS was 0.9 mm. A RMS value 
less than 1 mm was deemed an acceptable registration. With this registration in place, the 
coordinate locations of the film pin holes were also set in the plan. When the film is 
registered, the two sets of pin holes (the set selected on the film and the set known from 
the plan registration) were fused so the measured radiation and the planned radiation 
were connected.  
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3.4.3 Film Dosimetry 
 The Gafchromic® EBT film is the preferred type of film to use for phantom 
irradiations since it reliably gathers a large amount of information and does not need wet 
processing. As this type of film is not sensitive to room light, it can be cut into smaller 
pieces that are shaped to fit the phantom.  
 There have been studies to address the suitability of radiochromic film as a 
dosimeter in protons (Vatnitsky 1997; Nerbun 2005). Radiochromic film typically under-
responds at the distal end of the SOBP which is problematic for range measurements. The 
relative stopping power of the film has not been measured so it is not known whether 
having the film in the beam path would quantifiably change the range of the protons 
along the plane of the film. More studies would have to be made in the future to assure 
that film is an acceptable medium for this phantom in proton therapy. 
 The film calibration curves are shown in Figure 3.5. Trial 3 (shown in blue) was 
used for the calibration of the irradiated film. The standard deviation of each 
measurement was no more than 0.006 and the COV for the calibration curve used in the 
study centered around 0.8%.  The polynomial fit shown in Equation 3.1 was applied to 
the data with dose as a function of optical density. 
                                                                 Equation 3.1 xxxy 26.58614556.2861 23 
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Figure 3.5: Film Calibration Curve 
 
 In the RPC system, the TLD are used for dose point measurements and the film 
dose is scaled to these points. The 3% change seen in calibration curves for the proton 
beams and the photon beams (as stated in Section 0) would have been a greater concern 
had the film been used to directly measure the dose profiles. The low energy dependence 
of the film within batches provided confidence that the calibration using a 6 MV photon 
beam would not significantly affect the data. One concern was the under representation of 
dose seen at the distal end of the range by 5-10 % (Vatnitsky 1997). With the shifts 
between the planned and measured profiles being taken from the 75% - 25% region, this 
under-response of the film should not affect our measured displacements between the 
measured and calculated profiles.  
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3.4.4 Film Registration 
 The film was registered to the treatment plan by four pin pricks created by the 
dosimetry insert which can be seen in Figure 3.6. The coordinates of the pin pricks on the 
film were recorded and are shown in Table 3.8. Any setup error made with the phantom 
would appear once a comparison of the measured profiles to the calculated profiles was 
performed since the physical coordinates of the film would not match the expected 
coordinates in reference to the designated center of the phantom. Care was taken when 
loading and unloading the film from the dosimetry insert to keep from “doubly-pricking” 
the film. This can cause a mis-registration that can result in false range data from the 
measured profiles. 
 
 
Film coordinates sagittal 
TLD coordinates 
sagittal 
 
superior 
posterior 
superior 
anterior 
inferior 
posterior 
inferior 
anterior 
right 
posterior 
left 
anterior 
x 0 0 0 0 0 0 
y -47.8 54 -56.9 48.5 -4 4 
z 55.1 55.1 -48.5 -51.9 0 0 
       
Film coordinates coronal 
TLD coordinates 
coronal 
 superior left 
superior 
right 
inferior left 
inferior 
right 
right 
posterior 
left 
anterior 
x -42 52 -53.6 47 4 -4 
y 0 0 0 0 0 0 
z 55.4 46 -48.1 -50 0 0 
Table 3.8: 2D Film Registration 
 
 52  
 
Figure 3.6: Film Registration Points 
 
 Each film was uploaded into our in-house software for registration. The phantom 
name was selected along with the plane of the film. For example, Figure 3.6 was 
uploaded as a pelvis phantom with the coronal film on the left and the sagittal films on 
the right. The two sagittal film pieces were scanned and registered together. The “X” 
marks on the film were placed on the pin pricks using a magnified view of the film. 
These marks should align with the coordinates listed in Table 3.8. At this point, the film 
is registered to the phantom, converted to dose and scaled relative to the TLD point 
measurements. The phantom was registered to the treatment plan and to the film 
measurements. Dose profiles from the measured data and that calculated data can now be 
taken through the same planes. 
3.5 Treatment Procedure Evaluation 
3.5.1 TLD Comparison 
 The TLDs were read out 10 and 14 days post irradiation to lessen the effects of 
fading on the dose calculations. Each TLD capsule contained 2 aliquots of TLD. The 2 
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readings were averaged together to calculate the dose to the point of measurement. The 
measured TLD were compared to measured beam data from the use of both inserts. The 
CT scan of the phantom holding the imaging insert was used to create the treatment plan 
and these beams and dose points were placed on the image set from the dosimetry insert. 
Table 3.9 shows the TLD results from the 3 irradiations of Plan 1, the calculated 
dose from both inserts and the dose ratios. 
 
 Dose Points 
Meas. 
Dose (cGy) 
TLD 
Calc. Dose 
(cGy) 
Imaging 
Insert 
Calc. Dose 
(cGy) 
Dosimetry 
Insert 
Meas./Calc. 
Dose  
Imaging 
Insert 
Meas./Calc. 
Dose  
Dosimetry 
Insert 
PTV Right 589.8 600.2 596.0 0.983 0.990 
PTV Left 595.1 600.2 596.0 0.992 0.999 
Femur Right 242.1 247.3 249.6 0.979 0.970 
Trial 1 
Femur Left 240.4 243.8 245.2 0.986 0.980 
       
PTV Right 591.8 600.2 596.0 0.986 0.993 
PTV Left 592.8 600.2 596.0 0.988 0.995 
Femur Right 241.3 247.3 249.6 0.978 0.967 
Trial 2 
Femur Left 240.3 243.8 245.2 0.986 0.980 
       
PTV Right 589.6 600.2 596.0 0.982 0.989 
PTV Left 590.6 600.2 596.0 0.984 0.991 
Femur Right 244.2 247.3 249.6 0.988 0.978 
Trial 3 
Femur Left 238.2 243.8 245.2 0.977 0.972 
Table 3.9: TLD Data from Treatment Plan 1 
 
The column specifying the Measured/Calculated dose for the imaging insert is the ratio 
used to designate a passing dose comparison. The imaging insert was used for the CT 
simulation of the pelvis phantom and is the ideal candidate to use for the calculated dose 
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values. All of the measured planned target volume (PTV) values were well within 5% of 
the calculated dose from the TPS. 
 The pelvis phantom is intended for use by institutions to evaluate the treatment 
process for proton therapy. The phantom will be mailed pre-loaded with the dosimeters 
and is intended for one dose fraction before it is returned to the RPC. The phantom will 
need a CT simulation with the imaging insert for planning but it is not necessary to do a 
second scan for the dosimetry insert. Placing the beams on the dosimetry insert to 
calculate the expected dose does marginally improve (0.7%) the dose ratio. This is 
expected since the actual treatment is delivered to the dosimetry insert and not to the 
imaging insert. One option for compensating for the differences in calculated dose is to 
modify the pass criteria by 1% as 0.99 ratio is expected to be the best match between the 
measured and calculated dose. 
 It was expected that changing the calibration curve of the TPS to account for the 
actual stopping powers of the materials comprising the pelvis phantom would improve 
the dose comparison as it would provide a more accurate calculation by the TPS. The 
TLD results from Plan 2 are shown in Table 3.10. 
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 Dose Points 
Meas. 
Dose (cGy) 
- TLD 
Calc. Dose 
(cGy) - 
Imaging 
Insert 
Calc. Dose 
(cGy) - 
Dosimetry 
Insert 
Meas./Calc. 
Dose - 
Imaging 
Insert 
Meas./Calc. 
Dose - 
Dosimetry 
Insert 
PTV Right 575.9 600.2 594.9 0.960 0.968 
PTV Left 567.6 600.2 594.9 0.946 0.954 
Femur Right 241.4 252.2 250.4 0.957 0.964 
Trial 1 
Femur Left 239.6 248.1 247.8 0.966 0.967 
       
PTV Right 572.1 600.2 594.9 0.953 0.962 
PTV Left 565.6 600.2 594.9 0.942 0.951 
Femur Right 241.2 252.2 250.4 0.956 0.963 
Trial 2 
Femur Left 241.2 248.1 247.8 0.972 0.973 
       
PTV Right 578.9 600.2 594.9 0.965 0.973 
PTV Left 573.4 600.2 594.9 0.955 0.964 
Femur Right 241.1 252.2 250.4 0.956 0.963 
Trial 3 
Femur Left 240.9 248.1 247.8 0.971 0.972 
Table 3.10: TLD Data from Treatment Plan 2 
 
The measured dose from Plan 2 was on average 3% lower that its counterparts in 
Plan 1. Two of the TLD measurements (PTV Left in trials 1 and 2) differed more than 
5% from the calculated measurements. These did not pass the set criteria of 5%/3mm. By 
placing the beams to the dosimetry insert, all of the measured dose points come within 
the 5% range of the calculated dose. Looking at the film data brings more information to 
determine what changes the new stopping power values have created in the treatment 
plan and delivery. 
The lower TLD values were not expected from this plan. With the custom 
stopping power measurements in the calculation, the calculated and measured doses were 
expected to be nearly the same value. The dose difference actually increased when 
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compared to the first plan which did not account for the materials not being proton 
equivalent. It is not known of the TLD dose is a result of incorrect stopping power 
measurements or if the TLD do not respond as expected in a phantom of this size for 
protons. TLD irradiated in this phantom in other studies have been consistently 3 – 5% 
lower than the expected value. 
The TLD measured dose from each of the 3 trials for each plan were averaged 
together to measure the COV between the trials.  
 
 Plan 1 Plan 2 
 PTV Right 
PTV 
Left 
Femur 
Right 
Femur 
Left 
PTV 
Right 
PTV 
Left 
Femur 
Right 
Femur 
Left 
Predicted 
Dose (cGy) 600.2 600.2 247.3 243.8 600.2 600.2 252.2 248.1 
Meas. 
Dose 
Average 
(cGy) 
590.4 592.8 242.5 239.6 575.6 568.9 241.2 240.6 
COV 0.21% 0.38% 0.62% 0.52% 0.59% 0.71% 0.06% 0.35% 
Measured/
Calculated 
Dose 
0.984 0.988 0.981 0.983 0.959 0.948 0.957 0.970 
 
Table 3.11: Average Dose Across 3 Trials  
 
  The COVs for the PTV dose measurements were both less than 0.4% while the 
COVs for the femoral head dose measurements were less than 0.7% (as seen in Table 
3.11). Plan 2 also had a COV under 0.8% for the PTV and 0.4% for the femoral heads. 
The small variations between the trials show the phantom is able to reproduce TLD point 
measurements for a single plan. The reproducibility of the phantom measurements needs 
to be less than 3% to be able to securely use the phantom as an auditing tool. 
 A one-sample t-test was applied across the TLD data to check for statistical 
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significance. This was done for each TLD value across the 3 trials. Other than PTV left 
for Plan 2 (which was also the only dose measurement to be greater than 5% for two out 
of three trials) all of the TLD measurements had a p-value < 0.05 and were deemed 
statistically significant. 
3.5.2 Dose Profile Comparison 
 The dose profiles from the film were plotted along with the profiles taken from 
the TPS to compare dose profiles delivered during treatment. The fall-off regions along 
the edge of the dose profiles were characterized by a linear regression from the 80% to 
20% dose levels.  
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Figure 3.7: Plan 1 Trial 1 Right-Left Profile – Coronal Plane 
  
 Figure 3.7 shows the dose profiles along the beam path on the coronal plane. The 
displacement between the measured and calculated profile is shown at the 75%, 50% and 
25% levels. The average of these displacements was taken as the total displacement 
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between the profiles. For Plan 1, the right-left profile for all of the trials showed a 
displacement that was less than 3 mm. This direction is important as it is in the direction 
of the beam. The edges of the dose profiles correspond with the distal end of the range of 
the proton beam in this view. The plots from Trial 2 and Trial 3 can be viewed in the 
Appendix. 
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Figure 3.8: Plan 1 Trial 1 Superior-Inferior Profile – Coronal Plane 
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Figure 3.9: Plan 1 Trial 1 Superior-Inferior Profile – Sagittal Plane 
 
 The superior-inferior profile was captured on both the coronal and the sagittal 
films. These are shown in Figure 3.8 and Figure 3.9 respectively. Both displacements are 
less than 3 mm. Both film profiles appear to be shifted more towards the superior side of 
the phantom. This can be attributed to a shift in setup. As the phantom was set up using 
laser markings, a 1 mm setup error is not unlikely.  
 The lasers at the PTC-H are only calibrated with the gantry at 270º and are not 
normally used for patient setup. The on-board imaging system is used to localize patients 
through bony anatomy. When the phantom is on the treatment table, the only anatomy 
that could be used for localization would be the femur material which are two 
symmetrical cylinders. The concern that this would not provide the necessary landmarks 
to adequately position the phantom led to the use of the laser markings from the CT scan. 
 The registrations of the sagittal films also have a larger registration error than the 
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coronal films. For the set of films in Plan 1 Trial 1, the root mean square (RMS) of the 
2D registration for the coronal film was 0.24 mm while the sagittal film had a RMS of 
0.87 mm. This is most likely due to the fact that the sagittal film is cut in two separate 
pieces yet still registered as one solid piece. The film must be carefully scanned to 
minimize the registration error. For these reasons, a small difference in the superior-
inferior profiles between the two films is accepted. 
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Figure 3.10: Plan 1 Trial 1 Anterior-Posterior Profile – Sagittal Plane 
 
 The last profile garnered from the film was the anterior-posterior profile from the 
sagittal film as seen in Figure 3.10. For this trial, the displacement was 1 mm with good 
agreement along the entire profile. Note that the center of the film data is missing. This is 
where the film was cut to intersect with the coronal film. The solid black dots indicate the 
locations of the TLD. Note that the TLD are placed on either side of the cut in the film. 
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This enables the film dose of each piece of the sagittal film to be scaled to an absolute 
dose point. 
For Treatment Plan 2, the same profiles were taken to compare the measured and 
TPS predicted dose to the phantom. From the TLD dose in Section 3.5.1, we expected the 
film dose to be lower than calculated, but the range of the beam was still expected to 
follow the plan. In Figure 3.11, this is not what was seen. 
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Figure 3.11: Plan 2 Trial 1 Right Left Profile – Coronal Plane 
 
 The film dose profile extends well beyond the calculated dose profile on both the 
right and left sides of the target. The average displacement is -9.0 mm on the left side and 
6.0 mm on the right side. This does not portray a shift in the phantom positioning as the 
result of a setup error would shift the film profile in one direction. The other three film 
dose profiles (Figure 3.12, Figure 3.13, and Figure 3.14) were all within 3 mm of the TPS 
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dose profiles. The superior-inferior profiles in Figure 3.12 and Figure 3.13 showed a shift 
towards the superior edge of the phantom of 3 mm. This is believed to be from a shift in 
the initial setup of the phantom. The anterior-posterior profile in Figure 3.14 has no shift 
and is considered a perfect match with 0 mm displacement. 
0
1
2
3
4
5
6
7
8
-7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7
Distance (cm)
D
os
e 
(G
y)
RPC Film Institution Values TLD Left TLD Right RPC Regression Institution Regression
SuperiorInferior
New SP Plan Trial 1
Prostate Bladder
3 mm
2 mm
3 mm
Average
displacement
3 mm
 
Figure 3.12: Plan 2 Trial 1 Superior-Inferior Profile – Coronal Plane 
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Figure 3.13: Plan 2 Trial 1 Superior-Inferior Profile – Sagittal Plane 
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Figure 3.14: Plan 2 Trial 1 Anterior-Posterior Profile – Sagittal Plane 
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 Trials 2 and 3 from Treatment Plan 2 are shown in the Appendix and correspond 
well with Trial 1. For Trials 1 and 2 there were no failing film profiles outside of the 
Right-Left profiles. Trial 3 failed on the Superior-Inferior profile in the sagittal plane 
with a 4 mm displacement. 
 The film profiles for Plan 2 were also compared to the calculated dose profiles 
from the dosimetry insert on the verification plan. The relative stopping powers for the 
dosimetry insert (composed of HI Polystyrene) could have resulted in a measurable 
difference in the proton range. 
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Figure 3.15: Plan 2 Verification Trial 1 Right Left Profile – Coronal Plane 
 
 Comparing Figure 3.11 and Figure 3.15, there was an improvement in measured 
displacement with the beam fluence calculated on the dosimetry insert (versus the 
imaging insert). The verification plan’s margin (Figure 3.15) was still outside of the 
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accepted limits of 3mm. For trial 1 the average displacement was -7 mm on the left side 
and 5 mm on the right side. Trials 2 and 3 (listed in the Appendix) also failed the set 
criteria of 3 mm in the right left direction.  The other verification profiles from Plan 2 
(Figure 3.16 Figure 3.18) did not change beyond 1 mm in comparison to the Plan 2 
profiles in Figure 3.12 -Figure 3.14.   
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Figure 3.16: Plan 2 Verification Trial 1 Superior-Inferior Profile – Coronal Plane 
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Figure 3.17: Plan 2 Verification Trial 1 Superior-Inferior Profile – Sagittal Plane 
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Figure 3.18: Plan 2 Verification Trial 1 Anterior-Posterior Profile – Sagittal Plane 
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Overall the maximum shift between trials for both treatment plans was 2 mm. For 
instance, the shift in the anterior-posterior profile for Plan 1 was 1 mm for all 3 trials. For 
Plan 2 the superior-inferior profile in the sagittal plane was 3 mm for Trials 1 and 2 and 4 
mm for Trial 1 giving a 1mm shift between trials. This 2 mm agreement between trials 
shows the film profiles can be reproduced within our 3 mm margin. 
3.5.3 Treatment Plan 2 Quality Assurance 
With the large displacement in right-left profile for Treatment Plan 2, it was 
decided to perform a quality assurance test in the same style that would be done for a 
patient treatment. This test ensures that the plan calculated by the TPS is being delivered 
by the machine.  
The measured and calculated depth dose profiles were compared to one another 
and can be seen in Figure 3.19 and Figure 3.20. 
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Figure 3.19: Right Lateral QA Comparison 
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Figure 3.20: Left Lateral QA Comparison 
 
 A spline interpolation was performed to calculate the shift of the distal 90% of the 
measured beam profile and the calculated beam profile. The right lateral scan was shifted 
by 0.12 cm and the left lateral scan was shifted by 0.23 cm. These displacements were 
not large enough to account for the shifts seen in Figure 3.11. From this we concluded 
that the difference in beam profiles most likely is attributed to one of two things: 
 The effect of the protons streaming along the film plane and the difference in 
composition between the HI polystyrene and film itself, or 
 An error in measurement of the relative stopping power of the phantom materials 
and subsequent entry into the TPS 
By rotating the dosimetry insert 10º, the film would no longer be parallel to the beam and 
any streaming effects would be negated. Air gaps had already been eliminated by double-
loading the film in the dosimetry insert. 
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 The material stopping power measurements were only done once for each 
material. Though the comparison of the measured stopping powers and published 
literature values agreed within 5%, this difference could have been the source of the 
range differences. The range of the beam could have penetrated further than expected on 
both the left and right side of the target due to a discrepancy between the measured 
stopping powers and the actual stopping powers of the material. This suggests the 
stopping powers used in calculating Treatment Plan 2 were larger than the actual 
stopping power encountered by the protons. The new stopping powers input into the TPS 
were mainly increasing the assigned stopping power initially produced by the calibration 
curve from HU to relative SP. Given the chance, scanning the materials several times 
with different material widths might produce a more accurate relative stopping power. 
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Chapter 4 
Conclusions 
4.1 Summary 
This research was intended to evaluate the Radiological Physics Center’s pelvis 
phantom for use in auditing proton therapy treatment procedures. The guidelines set for a 
passing score were to have no more than a 5%/3mm difference between the measured 
dose and the calculated dose with a reproducibility of 3%. 
The first part of the project involved measuring the relative stopping powers of the 
materials used to construct the phantom. As the phantom was originally designed to 
evaluate photon IMRT procedures, the materials chosen were not necessarily proton-
equivalent. By using samples of the different materials in the pelvis phantom, the relative 
stopping powers were measured and plotted along with CT values assigned to the 
materials. Comparing the measured values to the HU-SP calibration curve used by the 
TPS, it was found that the stopping powers for the materials could be underestimated by 
5-10%. With this knowledge, the phantom was tested under two main conditions: 
 Using the patient calibration curve already in place by the TPS 
 Overriding the calibration curve to use material specific stopping powers 
The phantom was simulated and planned using the clinic procedures in place for a typical 
prostate treatment. Once the plan was approved, the dose to the target was scaled to 
deliver 6 Gy. The phantom was irradiated 3 separate times using Plan 1. All of the 
measured planned target volume (PTV) TLD values for Plan 1 were well within 5% of 
the calculated dose from the TPS. The COV for the PTV doses were both less than 0.4% 
while the COV for the femoral head doses were less than 0.7%. For Plan 1, all of the 
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trials for all 4 profiles showed a displacement that was less than 3 mm. 
The CT numbers were then overridden on the treatment plan to account for the 
actual stopping powers of the materials as previously measured. The beams were re-
calculated and the phantom was irradiated 3 separate times using Plan 2. The measured 
dose from Plan 2 was on average 3% lower that its counterparts in Plan 1. Two of the 
TLD measurements (PTV Left in trials 1 and 2) differed more than 5% from the 
calculated measurements. These did not pass the set criteria of 5%/3mm. By placing the 
beams to the dosimetry insert, all of the measured dose points came within the 5% range 
of the calculated dose. The right-left film dose profile extended well beyond the 
calculated dose profile on both the right and left sides of the target. The average 
displacement was -9.0 mm on the left side and 6.0 mm on the right side. For Trials 1 and 
2 there were no failing film profiles outside of the Right-Left profiles. Trial 3 failed on 
the Superior-Inferior profile in the sagittal plane with a 4 mm displacement. 
With the large displacements encountered with Plan 2, several measures were 
taken to confirm the results. The beams were placed on a “verification plan” which re-
calculated the beams based on the dosimetry insert instead of the imaging insert. This 
changed the displacements in the left-right direction. The verification plan’s margin was 
still outside of the accepted limits of 3mm. For trial 1 the average displacement was -7 
mm on the left side and 5 mm on the right side. 
4.2 Conclusions 
The hypothesis of this work was to use the pelvis phantom to confirm agreement 
between the measured and calculated dose within 5%/3mm with a reproducibility of 3%.  
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Plan 1 passed the established criteria and the results indicted the phantom would 
be an acceptable tool for auditing proton therapy.  With the phantom materials not being 
considered proton-equivalent materials, any institution that did not pass an audit 
involving the pelvis phantom could cite the phantom composition as a contributing factor 
to any discrepancies in dose margins. A solution to the difference in Hounsfield units and 
relative stopping powers of the materials was to directly input the measured stopping 
powers into the treatment planning system for dose calculation as was done for Plan 2. 
Plan 2 was intended to improve the agreements and instead introduced large 
displacements along the path of the beam. More work will have to be performed to find 
the source of the displacements. Plan 2 more closely represents the actual phantom 
composition (as compared to Plan 1 which did not use the corrected stopping powers) and 
should easily pass the set criteria of an agreement between the measured dose and 
calculated dose within 5%/3mm. At this time, the hypothesis was proven incorrect and 
the current version of the pelvis phantom was determined not suitable to evaluate proton 
therapy treatment procedures. With only one film profile failing the requirement, further 
studies could resolve the current issues and the phantom will be better suited for remote 
auditing of proton therapy treatment procedures. 
4.3 Future works 
The pelvis phantom shows promise as a valuable tool in the remote auditing 
proton therapy. One instance of future work on this phantom is to rotate the film in the 
phantom so the film is placed at an angle to the beam. This would remove any effect from 
the protons traveling along the film plane and having a change in density between the 
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dosimetry insert and the film.  
Many of the Gafchromic© film studies in the literature are from MD-55 film. An 
updated set of measurements for Gafchromic© EBT and EBT2 film in proton beams 
could be done to confirm previous findings have not been negated by an update in the 
film. 
As the pelvis phantom represents simple anatomy, and therefore a relatively 
simple treatment plan, once this phantom has been commissioned for use with protons, 
other relevant anatomical locations should also be tested. With more complicated 
treatment plans, the phantom’s ability to accurately measure the dose delivered to a target 
would become more imperative in order to audit procedures in the corresponding 
treatment sites. 
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Chapter 5 
Appendix 
The following figures are the additional the film profiles from trials 2 and 3 of each 
irradiation referred to in Section 3.5.2. 
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Figure 5.1: Plan 1 Trial 2 Right-Left Profile – Coronal Plane 
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Figure 5.2: Plan 1 Trial 2 Superior-Inferior Profile – Coronal Plane 
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Figure 5.3: Plan 1 Trial 2 Superior-Inferior Profile – Sagittal Plane 
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Figure 5.4: Plan 1 Trial 2 Anterior-Posterior Profile – Sagittal Plane 
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Figure 5.5: Plan 1 Trial 3 Right-Left Profile – Coronal Plane 
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Figure 5.6: Plan 1 Trial 3 Superior-Inferior Profile – Coronal Plane 
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Figure 5.7: Plan 1 Trial 3 Superior-Inferior Profile – Sagittal Plane 
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Figure 5.8: Plan 1 Trial 3 Anterior-Posterior Profile – Sagittal Plane 
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Figure 5.9: Plan 2 Trial 2 Right Left Profile – Coronal Plane 
 
 
 79  
0
1
2
3
4
5
6
7
8
-7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7
Distance (cm)
D
os
e 
(G
y)
RPC Film Institution Values TLD Left TLD Right RPC Regression Institution Regression
4 mm
SuperiorInferior Prostate Bladder
3 mm
3 mm
Average
displacement
3 mm
 
Figure 5.10: Plan 2 Trial 2 Superior-Inferior Profile – Coronal Plane 
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Figure 5.11: Plan 2 Trial 2 Superior-Inferior Profile – Sagittal Plane 
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Figure 5.12: Plan 2 Trial 2 Anterior-Posterior Profile – Sagittal Plane 
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Figure 5.13: Plan 2 Trial 3 Right Left Profile – Coronal Plane 
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Figure 5.14: Plan 2 Trial 3 Superior-Inferior Profile – Coronal Plane 
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Figure 5.15: Plan 2 Trial 3 Superior-Inferior Profile – Sagittal Plane 
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Figure 5.16: Plan 2 Trial 3 Anterior-Posterior Profile – Sagittal Plane 
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Figure 5.17: Plan 2 Verification Trial 2 Right Left Profile – Coronal Plane 
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Figure 5.18: Plan 2 Verification Trial 2 Superior-Inferior Profile – Coronal Plane 
 
-1
0
1
2
3
4
5
6
7
8
-7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7
Distance (cm)
D
os
e 
(G
y)
RPC Film Institution Values RPC Regression Inst Regression
Prostate SuperiorInferior Bladder
0 mm
 1 mm
2 mm
Average
displacement
1  mm
 
Figure 5.19: Plan 2 Verification Trial 2 Superior-Inferior Profile – Sagittal Plane 
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Figure 5.20: Plan 2 Verification Trial 2 Anterior-Posterior Profile – Sagittal Plane 
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Figure 5.21: Plan 2 Verification Trial 3 Right Left Profile – Coronal Plane 
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Figure 5.22: Plan 2 Verification Trial 3 Superior-Inferior Profile – Coronal Plane 
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Figure 5.23: Plan 2 Verification Trial 3 Superior-Inferior Profile – Sagittal Plane 
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Figure 5.24: Plan 2 Verification Trial 3 Anterior-Posterior Profile – Sagittal Plane 
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